靶向磷脂酰肌醇蛋白聚糖-3的正电子发射断层显像在肝细胞癌异种移植模型中检出亚厘米肿瘤
研究在肝细胞癌原位小鼠模型中评估了锆-89标记的靶向磷脂酰肌醇蛋白聚糖-3(GPC3)抗体偶联物(89Zr-αGPC3)用于PET/CT检测小型GPC3阳性肝细胞癌的效果。89Zr-αGPC3在肿瘤内快速蓄积且脱靶沉积少,免疫PET检出全部38个组织学确诊肿瘤,灵敏度100%,最小检出肿瘤直径330微米,特异度60%。作者认为该技术可能提高小肝细胞癌的诊断灵敏度并筛选GPC3阳性肿瘤用于靶向治疗,需开展人体试验评估其影响。
要点
- 89Zr-αGPC3免疫PET在肝细胞癌原位小鼠模型中检出全部38个组织学确诊肿瘤,灵敏度100%。
- 最小检出肿瘤直径为330微米,肿瘤与肝脏摄取比值高,空间分辨率良好。
- 5个PET/CT观察到的肿瘤中2个未获组织学确认,特异度60%。
核心结论
- 89Zr-αGPC3在GPC3阳性肿瘤中蓄积明显且脱靶滞留少,免疫PET灵敏度100%并可检出亚毫米肿瘤。
- 该技术可能提高小肝细胞癌的诊断灵敏度并筛选GPC3阳性肿瘤用于靶向治疗,需开展人体试验评估其影响。
研究设计与样本
- 研究为肝细胞癌原位小鼠模型研究,使用无胸腺nu/J小鼠,将GPC3阳性人肝细胞癌细胞系hepG2接种于肝包膜下。
- 荷瘤小鼠经尾静脉注射89Zr-αGPC3后第4天行PET/CT显像,随后切除肝脏对肿瘤进行识别、测量、对半切开并以500微米间隔连续切片。
- 以组织学切片肿瘤确认作为金标准,评估PET/CT对89Zr-αGPC3亲和肿瘤的灵敏度和特异度。
主要发现
- 43只动物中38只在组织学分析中可识别肿瘤。
- 89Zr-αGPC3注射后4小时内即在肿瘤内明显蓄积并随时间持续蓄积,脱靶沉积少且血液清除快。
- 89Zr-αGPC3免疫PET检出全部38个组织学确诊肿瘤,灵敏度100%,最小检出肿瘤直径330微米。
- 89Zr-αGPC3摄取的肿瘤与肝脏比值高,PET/CT上肿瘤检测空间分辨率良好。
- PET/CT观察到的5个肿瘤中2个未在组织学分析中识别,特异度60%。
关键数值与推荐
- 89Zr-αGPC3免疫PET检出38个组织学确诊肿瘤中的38个,灵敏度100%。
- 最小检出肿瘤直径为330微米。
- PET/CT观察到的5个肿瘤中2个未获组织学确认,特异度60%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文结论提出需开展人体试验评估该技术的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early intrahepatic recurrence is common after surgical resection of hepatocellular carcinoma (HCC) and leads to increased morbidity and mortality. Insensitive and nonspecific diagnostic imaging contributes to EIR and results in missed treatment opportunities. In addition, novel modalities are needed to identify targets amenable for targeted molecular therapy. In this study, we evaluated a zirconium-89 radiolabeled glypican-3 (GPC3) targeting antibody conjugate (89Zr-αGPC3) for use in positron emission tomography (PET) for detection of small, GPC3+ HCC in an orthotopic murine model. Athymic nu/J mice received hepG2, a GPC3+ human HCC cell line, into the hepatic subcapsular space. Tumor-bearing mice were imaged by PET/computerized tomography (CT) 4 days after tail vein injection of 89Zr-αGPC3. Livers were then excised for the tumors to be identified, measured, bisected, and then serially sectioned at 500 μm increments. Sensitivity and specificity of PET/CT for 89Zr-αGPC3-avid tumors were assessed using tumor confirmation on histologic sections as the gold standard. RESULTS: In tumor-bearing mice, 89Zr-αGPC3 avidly accumulated in the tumor within four hours of injection with ongoing accumulation over time. There was minimal off-target deposition and rapid bloodstream clearance. Thirty-eight of 43 animals had an identifiable tumor on histologic analysis. 89Zr-αGPC3 immuno-PET detected all 38 histologically confirmed tumors with a sensitivity of 100%, with the smallest tumor detected measuring 330 μm in diameter. Tumor-to-liver ratios of 89Zr-αGPC3 uptake were high, creating excellent spatial resolution for ease of tumor detection on PET/CT. Two of five tumors that were observed on PET/CT were not identified on histologic analysis, yielding a specificity of 60%. CONCLUSIONS: 89Zr-αGPC3 avidly accumulated in GPC3+ tumors with minimal off-target sequestration. 89Zr-αGPC3 immuno-PET yielded a sensitivity of 100% and detected sub-millimeter tumors. This technology may improve diagnostic sensitivity of small HCC and select GPC3+ tumors for targeted therapy. Human trials are warranted to assess its impact.
引用
- Labadie KP, Lehnert AL, Kenoyer AL, et al. Glypican-3 targeted positron emission tomography detects sub-centimeter tumors in a xenograft model of hepatocellular carcinoma. EJNMMI Res. 2023. PMID: 37103671. doi:10.1186/s13550-023-00980-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。